



Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference

February 7, 2011

MYSTIC, Conn. and DUBLIN, Feb. 7, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on Wednesday, February 16, 2011. Amarin's participation includes both a panel discussion on Cardiology at 7:45am ET and a company presentation at 9:15am ET. The conference will be held at the Roosevelt Hotel in New York City.

A live audio webcast of the presentation will be available at the following URL:

<http://www.wsw.com/webcast/leerink20/amrn>

About Amarin

Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (≥ 500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥ 200 and